ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Regeneron Pharmaceuticals, Inc. (REGN) shows an Average True Range (ATR) of 14.59 and an Enterprise Value of 97.83B. Its average trading volume over the past 3 months is 1.23M, indicating liquidity. These fundamental metrics provide insight into REGN's underlying financial health and market activity.
Regeneron Pharmaceuticals, Inc. (REGN) technical indicators as of August 1, 2025: the SMA 20 is -1.68%, SMA 50 at 0.64%, and SMA 200 at -18.37%. The RSI 14 value is 47.32, suggesting its current momentum. These technical analysis signals help assess REGN's price trends and potential future movements.
Regeneron Pharmaceuticals, Inc. (REGN) stock performance overview as of August 1, 2025: The 52-week high is $1,211.2 (currently -54.97% below), and the 52-week low is $476.49 (currently 14.48% above). Over the past year, REGN's performance is -49.43%, compared to the S&P 500's 14.84% change.
According to market data, Regeneron Pharmaceuticals, Inc. (REGN) stock's recent performance metrics show that over the last month, REGN is 1.97%, with a Year-to-Date (YTD) performance of -23.43%. Over the past year, the stock has seen a -49.43% change. These figures summarize REGN's price movements across various periods, reflecting its historical returns.
According to current financial data, REGN stock's P/E (TTM) ratio is 13.20, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for REGN, including P/S (4.19), P/B (2.02), and P/FCF (19.56), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.